Preamble: The National Institute for Occupational Safety and Health (NIOSH) Alert: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care

Appendix A · Drugs Considered Hazardous
General Approach to Handling Hazardous Drugs
In the Alert, NIOSH presents a standard precautions or universal precautions approach to handling hazardous drugs safely: that is, NIOSH recommends that all hazardous drugs be handled as outlined in the Alert. Therefore, no attempt has been made to perform drug risk assessments or propose exposure limits. The area of new drug development is rapidly evolving as unique approaches are being taken to treat cancer and other serious diseases.
Defining Hazardous Drugs
Hazardous drugs include those used for cancer chemotherapy, antiviral drugs, hormones, some bioengineered drugs, and other miscellaneous drugs. The definition of hazardous drugs used in the Alert is based on an ASHP definition that was originally developed in 1990 [ASHP 1990] . Thus the definition may not accurately reflect the toxicity criteria associated with the newer generation of pharmaceuticals entering the health care setting. For example, bioengineered drugs target specific sites in the body; and although they may or may not be toxic to the patient, some may not pose a risk to health care workers.
NIOSH and other organizations are still gathering data on the potential toxicity and health effects related to highly potent drugs and bioengineered drugs. Therefore, when working with any hazardous drug, health care workers should follow a standard precautions approach along with any recommendations included in the manufacturer's MSDSs.
ASHP Definition of Hazardous Drugs
ASHP defines hazardous drugs in their 1990 revision of Technical Assistance Bulletin on Handling Hazardous Drugs [ASHP 1990] . The bulletin gives criteria for identifying potentially hazardous drugs that should be handled in accordance with an established safety program [McDiarmid et al. 1991; Arrington and McDiarmid 1993] . The criteria are prioritized to reflect the hierarchy of potential toxicity described below. Since the hazardous drugs covered by the Alert were designed as therapeutic agents for humans, human toxicity profiles should be considered superior to any data from animal models or in vitro systems. Additional guidance for defining hazardous drugs is available in the following citations: carcinogenicity [61 Fed. Reg. 17960-18011 (1996b); IARC 2010] , teratogenicity [56 Fed. Reg. 63798-63826 (1991) ], developmental toxicity [56 Fed. Reg. 63798-63826 (1991) ], and reproductive toxicity [61 Fed. Reg. 56274-56322 (1996a) ]. Physical characteristics of the agents (such as liquid versus solid, or water versus lipid solubility) also need to be considered in determining the potential for occupational exposure. Reproductive toxicity † *ASHP [1990] definition of hazardous drugs 1. Genotoxicity (i.e., mutagenicity and clastogenicity in short-term test systems) 2. Carcinogenicity in animal models, in the patient population, or both, as reported by the International Agency for Research on Cancer (IARC) 3. Teratogenicity or fertility impairment in animal studies or in treated patients 4. Evidence of serious organ or other toxicity at low doses in animal models or treated patients. †
NIOSH Revision of ASHP Definition
All drugs have toxic side effects, but some exhibit toxicity at low doses. The level of toxicity reflects a continuum from relatively nontoxic to production of toxic effects in patients at low doses (for example, a few milligrams or less). For example, a daily therapeutic dose of 10 mg/day or a dose of 1 mg/kg per day in laboratory animals that produces serious organ toxicity, developmental toxicity, or reproductive toxicity has been used by the pharmaceutical industry to develop occupational exposure limits (OELs) of less than 10 µg/m 3 after applying appropriate uncertainty factors [Sargent and Kirk 1988; Naumann and Sargent 1997; tineoplastic drugs such as cyclophosphamide have immunosuppressant effects that proved beneficial for treating nonmalignant diseases such as rheumatoid arthritis and multiple sclerosis [Baker et al. 1987; Moody et al. 1987; Chabner et al. 1996; Abel 2000 ].
This document presents criteria and sources of information for determining whether a drug is hazardous. When a drug has been judged to be hazardous, the various precautions outlined in the Alert should be applied when handling that drug. Also included is a list of drugs that should be handled as hazardous. This list is based on a compilation of lists from four health care facilities, one drug manufacturers' organization, and NIOSH.
In addition to using the list of hazardous drugs presented here, each organization should create its own list of drugs considered to be hazardous. This document presents guidance for making such a facility-specific list (see section entitled How to Generate your own List of Hazardous Drugs) . Once this list is made, newly purchased drugs should be evaluated against the organization's hazardous drug criteria and added to the list if they are deemed hazardous.
Some organizations may have inadequate resources for determining their own list of hazardous drugs. If so, the sample list of hazardous drugs in this document will help employers and workers to determine when precautions are needed. However, reliance on such a published list is a concern because it quickly becomes outdated as new drugs continually enter the market or listed drugs are removed when additional information becomes available. NIOSH will update a list periodically, adding new drugs considered to be hazardous and removing those that require reclassification. This hazardous drug list will be posted on the NIOSH Web site at www.cdc.gov/niosh/ topics/hazdrug/.
How to Generate You Own List of Hazardous Drugs
The 
Examples of Hazardous Drugs
The following list contains a sampling of major hazardous drugs. The list (Table 1) In addition, 15 drugs were removed from the 2010 list. Nine of these are no longer available in the U.S., two are radio-pharmaceuticals that are regulated by the Nuclear Regulatory Agency and require special handling, and four are determined to not meet the criteria for a hazardous drug as defined by NIOSH [NIOSH 2004 [NIOSH , 2010 (Table 2 ). The OSHA hazard communication standard requires hazardous drugs to be handled using special precautions. BCG preparation should be done using aseptic techniques. To avoid cross-contamination, parenteral drugs should not be prepared in areas where BCG has been prepared. A separate area for the preparation of BCG suspension is recommended. All equipment, supplies, and receptacles in contact with BCG should be handled and disposed of as biohazardous. If preparation cannot be performed in a containment device, then respiratory protection, gloves and a gown should be worn to avoid inhalation or contact with BCG organisms. 
